_id
690db1e8ccc777a4e85d0c27
Ticker
ASPHF
Name
Ascentage Pharma Group International
Exchange
PINK
Address
Suzhou Industrial Park, Suzhou, China, 215000
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.ascentage.cn
Description
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Last Close
8.48
Volume
100
Current Price
8.48
Change
0
Last Updated
2026-01-20T15:47:17.671Z
Image
data:image/webp;base64,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
Ipo Date
-
Market Cap
3153317376
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.47825
Sentiment Sources
4
Current Quarter
2025-06-30
Revenue
31968416
Cost Of Revenue
21650000
Gross Profit
23740036
Operating Expenses
99521237
Operating Income
-75781201
Interest Expense
3802575
Pretax Income
-80066656
Net Income
-80812999
Eps
-0.2365782254578953
Dividends Per Share
-
Shares Outstanding
371853475
Income Tax Expense
5512000
EBITDA
-515708999
Operating Margin
-237.05022169381178
Total Other Income Expense Net
-31328000
Cash
1661454000
Short Term Investments
-
Receivables
78362000
Inventories
8591000
Total Current Assets
1908720000
Property Plant Equipment
871961000
Total Assets
3046144000
Payables
118676000
Short Term Debt
833783000
Long Term Debt
882382000
Total Liabilities
2370235000
Equity
665997000
Bs_currency_symbol
CNY
Depreciation
43790000
Change In Working Capital
-
Cash From Operations
-62692151
Capital Expenditures
20037000
Cash From Investing
-96373491
Cash From Financing
133637032
Net Change In Cash
106121461
Cf_currency_symbol
-
PE
-
PB
4.349406842613406
ROE
-12.13413859221588
ROA
-2.6529605625997985
FCF
-82729151
Fcf Percent
-2.587840166994824
Piotroski FScore
1
Health Score
12
Deep Value Investing Score
3
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
1
Growth Investing Score
1
Momentum Investing Score
3.5
Net Net Investing Score
2
Quality Investing Score
1
Value Investing Score
1.5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
31968416
Quarters > 0 > income Statement > cost Of Revenue
21650000
Quarters > 0 > income Statement > gross Profit
23740036
Quarters > 0 > income Statement > operating Expenses
99521237
Quarters > 0 > income Statement > operating Income
-75781201
Quarters > 0 > income Statement > interest Expense
3802575
Quarters > 0 > income Statement > pretax Income
-80066656
Quarters > 0 > income Statement > net Income
-80812999
Quarters > 0 > income Statement > eps
-0.2365782254578953
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
341591027
Quarters > 0 > income Statement > income Tax Expense
5512000
Quarters > 0 > income Statement > EBITDA
-515708999
Quarters > 0 > income Statement > operating Margin
-237.05022169381178
Quarters > 0 > income Statement > total Other Income Expense Net
-31328000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
1661454000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
78362000
Quarters > 0 > balance Sheet > inventories
8591000
Quarters > 0 > balance Sheet > total Current Assets
1908720000
Quarters > 0 > balance Sheet > property Plant Equipment
871961000
Quarters > 0 > balance Sheet > total Assets
3046144000
Quarters > 0 > balance Sheet > payables
118676000
Quarters > 0 > balance Sheet > short Term Debt
833783000
Quarters > 0 > balance Sheet > long Term Debt
882382000
Quarters > 0 > balance Sheet > total Liabilities
2370235000
Quarters > 0 > balance Sheet > equity
665997000
Quarters > 0 > balance Sheet > currency_symbol
CNY
Quarters > 0 > cash Flow > net Income
-590768000
Quarters > 0 > cash Flow > depreciation
43790000
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
-62692151
Quarters > 0 > cash Flow > capital Expenditures
20037000
Quarters > 0 > cash Flow > cash From Investing
-96373491
Quarters > 0 > cash Flow > cash From Financing
133637032
Quarters > 0 > cash Flow > net Change In Cash
106121461
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.2365782254578953
Quarters > 0 > ratios > PB
4.349406842613406
Quarters > 0 > ratios > ROE
-12.13413859221588
Quarters > 0 > ratios > ROA
-2.6529605625997985
Quarters > 0 > ratios > FCF
-82729151
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-2.587840166994824
Quarters > 0 > health Score
12
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
156904000
Quarters > 1 > income Statement > cost Of Revenue
14026000
Quarters > 1 > income Statement > gross Profit
142878000
Quarters > 1 > income Statement > operating Expenses
700591000
Quarters > 1 > income Statement > operating Income
-557713000
Quarters > 1 > income Statement > interest Expense
64455000
Quarters > 1 > income Statement > pretax Income
-558150000
Quarters > 1 > income Statement > net Income
-568434000
Quarters > 1 > income Statement > eps
-1.920226223440644
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
296024496
Quarters > 1 > income Statement > income Tax Expense
10356000
Quarters > 1 > income Statement > EBITDA
-467217000
Quarters > 1 > income Statement > operating Margin
-355.44855453015856
Quarters > 1 > income Statement > total Other Income Expense Net
-437000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
1236578000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
99074000
Quarters > 1 > balance Sheet > inventories
6597000
Quarters > 1 > balance Sheet > total Current Assets
1474162000
Quarters > 1 > balance Sheet > property Plant Equipment
905860000
Quarters > 1 > balance Sheet > total Assets
2617810000
Quarters > 1 > balance Sheet > payables
91966000
Quarters > 1 > balance Sheet > short Term Debt
779062000
Quarters > 1 > balance Sheet > long Term Debt
868642000
Quarters > 1 > balance Sheet > total Liabilities
2343648000
Quarters > 1 > balance Sheet > equity
264194000
Quarters > 1 > balance Sheet > currency_symbol
CNY
Quarters > 1 > cash Flow > net Income
-558256000
Quarters > 1 > cash Flow > depreciation
45857000
Quarters > 1 > cash Flow > change In Working Capital
110966000
Quarters > 1 > cash Flow > cash From Operations
243034000
Quarters > 1 > cash Flow > capital Expenditures
7763000
Quarters > 1 > cash Flow > cash From Investing
-230757000
Quarters > 1 > cash Flow > cash From Financing
-82139000
Quarters > 1 > cash Flow > net Change In Cash
-144948000
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-1.920226223440644
Quarters > 1 > ratios > PB
9.501683331491254
Quarters > 1 > ratios > ROE
-215.15780070705617
Quarters > 1 > ratios > ROA
-21.71410453776248
Quarters > 1 > ratios > FCF
235271000
Quarters > 1 > ratios > Piotroski FScore
2
Quarters > 1 > ratios > fcf Percent
1.4994582674756538
Quarters > 1 > health Score
28
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
823746000
Quarters > 2 > income Statement > cost Of Revenue
15059000
Quarters > 2 > income Statement > gross Profit
808687000
Quarters > 2 > income Statement > operating Expenses
620704000
Quarters > 2 > income Statement > operating Income
187983000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
162895000
Quarters > 2 > income Statement > net Income
163001000
Quarters > 2 > income Statement > eps
0.5506334854126397
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
296024496
Quarters > 2 > income Statement > income Tax Expense
69000
Quarters > 2 > income Statement > EBITDA
229586000
Quarters > 2 > income Statement > operating Margin
22.820505349950107
Quarters > 2 > income Statement > total Other Income Expense Net
-25088000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
1100314000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
852807000
Quarters > 2 > balance Sheet > inventories
10718000
Quarters > 2 > balance Sheet > total Current Assets
1963839000
Quarters > 2 > balance Sheet > property Plant Equipment
931183000
Quarters > 2 > balance Sheet > total Assets
3107070000
Quarters > 2 > balance Sheet > payables
83083000
Quarters > 2 > balance Sheet > short Term Debt
729540000
Quarters > 2 > balance Sheet > long Term Debt
959142000
Quarters > 2 > balance Sheet > total Liabilities
2330631000
Quarters > 2 > balance Sheet > equity
766399000
Quarters > 2 > balance Sheet > currency_symbol
CNY
Quarters > 2 > cash Flow > net Income
163001000
Quarters > 2 > cash Flow > depreciation
47312000
Quarters > 2 > cash Flow > change In Working Capital
-
Quarters > 2 > cash Flow > cash From Operations
-354391000
Quarters > 2 > cash Flow > capital Expenditures
16526000
Quarters > 2 > cash Flow > cash From Investing
-131278000
Quarters > 2 > cash Flow > cash From Financing
396906000
Quarters > 2 > cash Flow > net Change In Cash
952434000
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
0.5506334854126397
Quarters > 2 > ratios > PB
3.2754318913255367
Quarters > 2 > ratios > ROE
21.268425454626115
Quarters > 2 > ratios > ROA
5.246132208157524
Quarters > 2 > ratios > FCF
-370917000
Quarters > 2 > ratios > Piotroski FScore
2
Quarters > 2 > ratios > fcf Percent
-0.45028079043782915
Quarters > 2 > health Score
46
Quarters > 3 > quarter
2023-12-31
Quarters > 3 > income Statement > revenue
79283000
Quarters > 3 > income Statement > cost Of Revenue
12389000
Quarters > 3 > income Statement > gross Profit
66894000
Quarters > 3 > income Statement > operating Expenses
598962000
Quarters > 3 > income Statement > operating Income
-532068000
Quarters > 3 > income Statement > interest Expense
5994314
Quarters > 3 > income Statement > pretax Income
-533259000
Quarters > 3 > income Statement > net Income
-523286000
Quarters > 3 > income Statement > eps
-1.8041510941702013
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
290045552
Quarters > 3 > income Statement > income Tax Expense
-9896000
Quarters > 3 > income Statement > EBITDA
-492673000
Quarters > 3 > income Statement > operating Margin
-671.099731342154
Quarters > 3 > income Statement > total Other Income Expense Net
-1191000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
1069296000
Quarters > 3 > balance Sheet > short Term Investments
6557000
Quarters > 3 > balance Sheet > receivables
145893000
Quarters > 3 > balance Sheet > inventories
16167000
Quarters > 3 > balance Sheet > total Current Assets
1344178000
Quarters > 3 > balance Sheet > property Plant Equipment
957232000
Quarters > 3 > balance Sheet > total Assets
2500393000
Quarters > 3 > balance Sheet > payables
72445000
Quarters > 3 > balance Sheet > short Term Debt
616404000
Quarters > 3 > balance Sheet > long Term Debt
1166267000
Quarters > 3 > balance Sheet > total Liabilities
2429761000
Quarters > 3 > balance Sheet > equity
60417000
Quarters > 3 > balance Sheet > currency_symbol
CNY
Quarters > 3 > cash Flow > net Income
-523286000
Quarters > 3 > cash Flow > depreciation
47619000
Quarters > 3 > cash Flow > change In Working Capital
-69012000
Quarters > 3 > cash Flow > cash From Operations
-357613000
Quarters > 3 > cash Flow > capital Expenditures
12133000
Quarters > 3 > cash Flow > cash From Investing
86696000
Quarters > 3 > cash Flow > cash From Financing
-86883000
Quarters > 3 > cash Flow > net Change In Cash
-351943000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-1.8041510941702013
Quarters > 3 > ratios > PB
40.710169008060646
Quarters > 3 > ratios > ROE
-866.1237731102173
Quarters > 3 > ratios > ROA
-20.928150094805098
Quarters > 3 > ratios > FCF
-369746000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-4.663622718615592
Quarters > 3 > health Score
9
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
980650000
Annuals > 0 > income Statement > cost Of Revenue
29085000
Annuals > 0 > income Statement > gross Profit
951565000
Annuals > 0 > income Statement > operating Expenses
1321295000
Annuals > 0 > income Statement > operating Income
-369730000
Annuals > 0 > income Statement > interest Expense
64455000
Annuals > 0 > income Statement > pretax Income
-395255000
Annuals > 0 > income Statement > net Income
-405433000
Annuals > 0 > income Statement > eps
-1.3695927380280042
Annuals > 0 > income Statement > dividends Per Share
0
Annuals > 0 > income Statement > shares Outstanding
296024496
Annuals > 0 > income Statement > income Tax Expense
10425000
Annuals > 0 > income Statement > EBITDA
-237631000
Annuals > 0 > income Statement > operating Margin
-37.70254423086728
Annuals > 0 > income Statement > total Other Income Expense Net
-25525000
Annuals > 0 > income Statement > currency_symbol
CNY
Annuals > 0 > balance Sheet > cash
1236578000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
99074000
Annuals > 0 > balance Sheet > inventories
6597000
Annuals > 0 > balance Sheet > total Current Assets
1474162000
Annuals > 0 > balance Sheet > property Plant Equipment
905860000
Annuals > 0 > balance Sheet > total Assets
2617810000
Annuals > 0 > balance Sheet > payables
91966000
Annuals > 0 > balance Sheet > short Term Debt
779062000
Annuals > 0 > balance Sheet > long Term Debt
868642000
Annuals > 0 > balance Sheet > total Liabilities
2343648000
Annuals > 0 > balance Sheet > equity
264194000
Annuals > 0 > balance Sheet > currency_symbol
CNY
Annuals > 0 > cash Flow > net Income
-395255000
Annuals > 0 > cash Flow > depreciation
93169000
Annuals > 0 > cash Flow > change In Working Capital
110966000
Annuals > 0 > cash Flow > cash From Operations
-111357000
Annuals > 0 > cash Flow > capital Expenditures
24289000
Annuals > 0 > cash Flow > cash From Investing
-362035000
Annuals > 0 > cash Flow > cash From Financing
314767000
Annuals > 0 > cash Flow > net Change In Cash
-144948000
Annuals > 0 > cash Flow > currency_symbol
CNY
Annuals > 0 > ratios > PE
-1.3695927380280042
Annuals > 0 > ratios > PB
9.501683331491254
Annuals > 0 > ratios > ROE
-153.46033596523768
Annuals > 0 > ratios > ROA
-15.487487632792297
Annuals > 0 > ratios > FCF
-135646000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-0.13832254117167184
Annuals > 0 > health Score
8
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
221984000
Annuals > 1 > income Statement > cost Of Revenue
30543000
Annuals > 1 > income Statement > gross Profit
191441000
Annuals > 1 > income Statement > operating Expenses
1064077000
Annuals > 1 > income Statement > operating Income
-872636000
Annuals > 1 > income Statement > interest Expense
96057000
Annuals > 1 > income Statement > pretax Income
-932862000
Annuals > 1 > income Statement > net Income
-925637000
Annuals > 1 > income Statement > eps
-3.278920995009732
Annuals > 1 > income Statement > dividends Per Share
0
Annuals > 1 > income Statement > shares Outstanding
282299269
Annuals > 1 > income Statement > income Tax Expense
-7150000
Annuals > 1 > income Statement > EBITDA
-743610000
Annuals > 1 > income Statement > operating Margin
-393.10761135937724
Annuals > 1 > income Statement > total Other Income Expense Net
-60226000
Annuals > 1 > income Statement > currency_symbol
CNY
Annuals > 1 > balance Sheet > cash
1069296000
Annuals > 1 > balance Sheet > short Term Investments
31094000
Annuals > 1 > balance Sheet > receivables
145893000
Annuals > 1 > balance Sheet > inventories
16167000
Annuals > 1 > balance Sheet > total Current Assets
1344178000
Annuals > 1 > balance Sheet > property Plant Equipment
957232000
Annuals > 1 > balance Sheet > total Assets
2500393000
Annuals > 1 > balance Sheet > payables
72445000
Annuals > 1 > balance Sheet > short Term Debt
616404000
Annuals > 1 > balance Sheet > long Term Debt
1166267000
Annuals > 1 > balance Sheet > total Liabilities
2429761000
Annuals > 1 > balance Sheet > equity
60417000
Annuals > 1 > balance Sheet > currency_symbol
CNY
Annuals > 1 > cash Flow > net Income
-932862000
Annuals > 1 > cash Flow > depreciation
93195000
Annuals > 1 > cash Flow > change In Working Capital
-9146000
Annuals > 1 > cash Flow > cash From Operations
-726077000
Annuals > 1 > cash Flow > capital Expenditures
56844000
Annuals > 1 > cash Flow > cash From Investing
21922000
Annuals > 1 > cash Flow > cash From Financing
368751000
Annuals > 1 > cash Flow > net Change In Cash
-307591000
Annuals > 1 > cash Flow > currency_symbol
CNY
Annuals > 1 > ratios > PE
-3.278920995009732
Annuals > 1 > ratios > PB
39.622917409338434
Annuals > 1 > ratios > ROE
-1532.080374728967
Annuals > 1 > ratios > ROA
-37.01966050936793
Annuals > 1 > ratios > FCF
-782921000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-3.5269253639901974
Annuals > 1 > health Score
8
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
209711000
Annuals > 2 > income Statement > cost Of Revenue
21998000
Annuals > 2 > income Statement > gross Profit
187713000
Annuals > 2 > income Statement > operating Expenses
1031827000
Annuals > 2 > income Statement > operating Income
-883407000
Annuals > 2 > income Statement > interest Expense
52785000
Annuals > 2 > income Statement > pretax Income
-887172000
Annuals > 2 > income Statement > net Income
-882924000
Annuals > 2 > income Statement > eps
-3.3486097315554106
Annuals > 2 > income Statement > dividends Per Share
0
Annuals > 2 > income Statement > shares Outstanding
263668827
Annuals > 2 > income Statement > income Tax Expense
-4248000
Annuals > 2 > income Statement > EBITDA
-835986000
Annuals > 2 > income Statement > operating Margin
-421.249719852559
Annuals > 2 > income Statement > total Other Income Expense Net
-37362000
Annuals > 2 > income Statement > currency_symbol
CNY
Annuals > 2 > balance Sheet > cash
1492240000
Annuals > 2 > balance Sheet > short Term Investments
11905000
Annuals > 2 > balance Sheet > receivables
54356000
Annuals > 2 > balance Sheet > inventories
9448000
Annuals > 2 > balance Sheet > total Current Assets
1636488000
Annuals > 2 > balance Sheet > property Plant Equipment
648722000
Annuals > 2 > balance Sheet > total Assets
2830261000
Annuals > 2 > balance Sheet > payables
95559000
Annuals > 2 > balance Sheet > short Term Debt
518383000
Annuals > 2 > balance Sheet > long Term Debt
1265200000
Annuals > 2 > balance Sheet > total Liabilities
2421603000
Annuals > 2 > balance Sheet > equity
408658000
Annuals > 2 > balance Sheet > currency_symbol
CNY
Annuals > 2 > cash Flow > net Income
-882924000
Annuals > 2 > cash Flow > depreciation
60916000
Annuals > 2 > cash Flow > change In Working Capital
-5906000
Annuals > 2 > cash Flow > cash From Operations
-653915000
Annuals > 2 > cash Flow > capital Expenditures
203288000
Annuals > 2 > cash Flow > cash From Investing
-384612000
Annuals > 2 > cash Flow > cash From Financing
619268000
Annuals > 2 > cash Flow > net Change In Cash
-361247000
Annuals > 2 > cash Flow > currency_symbol
CNY
Annuals > 2 > ratios > PE
-3.3486097315554106
Annuals > 2 > ratios > PB
5.471351724326944
Annuals > 2 > ratios > ROE
-216.05450034013774
Annuals > 2 > ratios > ROA
-31.195850842024818
Annuals > 2 > ratios > FCF
-857203000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-4.087544287138014
Annuals > 2 > health Score
11
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
27910000
Annuals > 3 > income Statement > cost Of Revenue
3328000
Annuals > 3 > income Statement > gross Profit
24582000
Annuals > 3 > income Statement > operating Expenses
847206000
Annuals > 3 > income Statement > operating Income
-933170000
Annuals > 3 > income Statement > interest Expense
16731000
Annuals > 3 > income Statement > pretax Income
-832249000
Annuals > 3 > income Statement > net Income
-782424000
Annuals > 3 > income Statement > eps
-3.0729651061612073
Annuals > 3 > income Statement > dividends Per Share
0
Annuals > 3 > income Statement > shares Outstanding
254615322
Annuals > 3 > income Statement > income Tax Expense
-49825000
Annuals > 3 > income Statement > EBITDA
-915987000
Annuals > 3 > income Statement > operating Margin
-3343.496954496596
Annuals > 3 > income Statement > total Other Income Expense Net
37586000
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
1743821000
Annuals > 3 > balance Sheet > short Term Investments
4145000
Annuals > 3 > balance Sheet > receivables
53968000
Annuals > 3 > balance Sheet > inventories
3930000
Annuals > 3 > balance Sheet > total Current Assets
1885280000
Annuals > 3 > balance Sheet > property Plant Equipment
844368000
Annuals > 3 > balance Sheet > total Assets
2940060000
Annuals > 3 > balance Sheet > payables
70861000
Annuals > 3 > balance Sheet > short Term Debt
49451000
Annuals > 3 > balance Sheet > long Term Debt
1026592000
Annuals > 3 > balance Sheet > total Liabilities
1705323000
Annuals > 3 > balance Sheet > equity
1234737000
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-782424000
Annuals > 3 > cash Flow > depreciation
27526000
Annuals > 3 > cash Flow > change In Working Capital
-57898000
Annuals > 3 > cash Flow > cash From Operations
-604679000
Annuals > 3 > cash Flow > capital Expenditures
435415000
Annuals > 3 > cash Flow > cash From Investing
-466522000
Annuals > 3 > cash Flow > cash From Financing
1781387000
Annuals > 3 > cash Flow > net Change In Cash
686907000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-3.0729651061612073
Annuals > 3 > ratios > PB
1.748662209490766
Annuals > 3 > ratios > ROE
-63.36766453098919
Annuals > 3 > ratios > ROA
-26.612518111875268
Annuals > 3 > ratios > FCF
-1040094000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-37.26599785023289
Annuals > 3 > health Score
24
Valuation > metrics > PE
-0.2365782254578953
Valuation > metrics > PB
4.349406842613406
Valuation > final Score
36.505931573865944
Valuation > verdict
45.0% Overvalued
Profitability > metrics > ROE
-12.13413859221588
Profitability > metrics > ROA
-4.233884435642735
Profitability > metrics > Net Margin
-2.5279012572909463
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
3.558927442616108
Risk > metrics > Interest Coverage
-19.928916852396075
Risk > final Score
-74
Risk > verdict
High
Liquidity > metrics > Current Ratio
2.003991772874213
Liquidity > metrics > Quick Ratio
1.9949719620477102
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
20
Prev Valuations > 1
67.24568108674464
Prev Valuations > 2
20
Prev Profitabilities > 0
0
Prev Profitabilities > 1
95
Prev Profitabilities > 2
0
Prev Risks > 0
-29
Prev Risks > 1
17
Prev Risks > 2
-349
Prev Liquidities > 0
92
Prev Liquidities > 1
100
Prev Liquidities > 2
99
Updated At
2026-01-20T21:25:18.413Z
Earnings History > 0 > period
2021-03-31
Earnings History > 0 > report Date
2021-06-30
Earnings History > 0 > date
2021-03-31
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
CNY
Earnings History > 0 > eps Actual
-0.1181
Earnings History > 0 > eps Estimate
0
Earnings History > 0 > eps Difference
-0.1181
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2020-12-31
Earnings History > 1 > report Date
2021-03-31
Earnings History > 1 > date
2020-12-31
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
CNY
Earnings History > 1 > eps Actual
-0.1163
Earnings History > 1 > eps Estimate
0
Earnings History > 1 > eps Difference
-0.1163
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2020-09-30
Earnings History > 2 > report Date
2020-12-31
Earnings History > 2 > date
2020-09-30
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
CNY
Earnings History > 2 > eps Actual
-0.1232
Earnings History > 2 > eps Estimate
0
Earnings History > 2 > eps Difference
-0.1232
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2020-06-30
Earnings History > 3 > report Date
2020-09-30
Earnings History > 3 > date
2020-06-30
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
CNY
Earnings History > 3 > eps Actual
-0.1184
Earnings History > 3 > eps Estimate
0
Earnings History > 3 > eps Difference
-0.1184
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2020-03-31
Earnings History > 4 > report Date
2020-06-30
Earnings History > 4 > date
2020-03-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
CNY
Earnings History > 4 > eps Actual
-0.1081
Earnings History > 4 > eps Estimate
0
Earnings History > 4 > eps Difference
-0.1081
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2019-12-31
Earnings History > 5 > report Date
2020-03-31
Earnings History > 5 > date
2019-12-31
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
CNY
Earnings History > 5 > eps Actual
-0.1079
Earnings History > 5 > eps Estimate
0
Earnings History > 5 > eps Difference
-0.1079
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2019-09-30
Earnings History > 6 > report Date
2019-12-31
Earnings History > 6 > date
2019-09-30
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
CNY
Earnings History > 6 > eps Actual
-0.4469
Earnings History > 6 > eps Estimate
0
Earnings History > 6 > eps Difference
-0.4469
Earnings History > 6 > surprise Percent
-
Earnings History > 7 > period
2019-06-30
Earnings History > 7 > report Date
2019-09-30
Earnings History > 7 > date
2019-06-30
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
CNY
Earnings History > 7 > eps Actual
-0.4355
Earnings History > 7 > eps Estimate
0
Earnings History > 7 > eps Difference
-0.4355
Earnings History > 7 > surprise Percent
-
Earnings History > 8 > period
2019-03-31
Earnings History > 8 > report Date
2019-06-30
Earnings History > 8 > date
2019-03-31
Earnings History > 8 > before After Market
-
Earnings History > 8 > currency
CNY
Earnings History > 8 > eps Actual
-0.474
Earnings History > 8 > eps Estimate
0
Earnings History > 8 > eps Difference
-0.474
Earnings History > 8 > surprise Percent
-
Earnings History > 9 > period
2018-12-31
Earnings History > 9 > report Date
2019-03-31
Earnings History > 9 > date
2018-12-31
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
CNY
Earnings History > 9 > eps Actual
-0.4849
Earnings History > 9 > eps Estimate
0
Earnings History > 9 > eps Difference
-0.4849
Earnings History > 9 > surprise Percent
-
Earnings History > 10 > period
2018-09-30
Earnings History > 10 > report Date
2018-12-31
Earnings History > 10 > date
2018-09-30
Earnings History > 10 > before After Market
-
Earnings History > 10 > currency
CNY
Earnings History > 10 > eps Actual
-0.2314
Earnings History > 10 > eps Estimate
0
Earnings History > 10 > eps Difference
-0.2314
Earnings History > 10 > surprise Percent
-
Earnings History > 11 > period
2018-06-30
Earnings History > 11 > report Date
2018-09-30
Earnings History > 11 > date
2018-06-30
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
CNY
Earnings History > 11 > eps Actual
-0.2318
Earnings History > 11 > eps Estimate
0
Earnings History > 11 > eps Difference
-0.2318
Earnings History > 11 > surprise Percent
-
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AAscentage Pharma Group International (OTCMKTS:ASPHF) Sees Significant Increase in Short Interest Defense World
Read more →(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Ascentage Pharma Group International
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2021-03-31
EPS Actual
-0.1181
EPS Estimate
0
EPS Difference
-0.1181
Surprise Percent
0%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.